Hengrui Medicine (600276.SH): Ruiweilutamide Tablets Receives Drug Clinical Trial Approval Notice

Zhitong Finance APP News, Hengrui Pharmaceuticals (600276.SH) announced that recently, the company received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration for Rezvilutamide Tablets, and will soon conduct clinical trials for prostate cancer. Specifically: a multicenter, randomized, double-blind, placebo-controlled Phase III clinical study of Rezvilutamide combined with androgen deprivation therapy (ADT) versus placebo combined with ADT for the efficacy and safety in the treatment of high-risk localized or high-risk biochemical recurrence (BCR) prostate cancer after radical surgery/radiotherapy.